Enanta PharmaceuticalsENTA
ENTA
About: Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Employees: 131
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
3% less funds holding
Funds holding: 110 [Q3] → 107 (-3) [Q4]
7.2% less ownership
Funds ownership: 101.15% [Q3] → 93.95% (-7.2%) [Q4]
21% less call options, than puts
Call options by funds: $56K | Put options by funds: $71K
48% less capital invested
Capital invested by funds: $222M [Q3] → $114M (-$108M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
190%
upside
Avg. target
$19.50
215%
upside
High target
$21
239%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Roy Buchanan 32% 1-year accuracy 8 / 25 met price target | 239%upside $21 | Market Outperform Reiterated | 11 Feb 2025 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 72 / 154 met price target | 190%upside $18 | Buy Reiterated | 11 Feb 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET. A live webcast of the event will be accessible by visiting the “Events and Presentations” section.
Neutral
Business Wire
1 week ago
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company's respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Fall.
Positive
Zacks Investment Research
1 month ago
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
1 month ago
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.
Neutral
Business Wire
1 month ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV.
Neutral
Business Wire
2 months ago
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Events and Present.
Neutral
Business Wire
2 months ago
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i.
Positive
Zacks Investment Research
3 months ago
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neutral
Business Wire
3 months ago
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoi.
Neutral
Business Wire
3 months ago
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory sync.
Charts implemented using Lightweight Charts™